Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.41% | -54.12% | -11.07% | 83.80% | 5.46% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,964.22% | 162.00% | 143.61% | -208.95% | -114.01% |
| Change in Net Operating Assets | 0.34% | 142.96% | -120.98% | -42.61% | 68.99% |
| Cash from Operations | -50.07% | -39.95% | -19.84% | -26.16% | 25.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -477.10% | 92,855.74% | -45.07% | -41.51% | 165.55% |
| Cash from Investing | -477.10% | 92,855.74% | -45.07% | -41.51% | 165.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 62,255.54% | 5,600.00% | 38.49% | -96.25% | 47.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -83.87% | 78.96% | -6,482.05% | -- |
| Cash from Financing | 59,079.62% | 9,704.00% | 38.66% | -136.33% | 103.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.45% | 128.01% | 16.71% | -164.19% | 118.18% |